The FDA denied reports suggesting plans to abandon certain advisory committee meetings, reaffirming ongoing review processes amid scrutiny over Covid vaccine safety data linking shots to child deaths, based on VAERS database analysis. Meanwhile, regulatory updates include new CPT codes for AI and peripheral artery disease services introduced by AMA, and continued uncertainties surround pharma investments in UK sites with companies like AstraZeneca reassessing commitments. These developments indicate a dynamic regulatory landscape with significant implications for industry and public health policy.